Flourishing Nexus recently won runner up in the innovation category of the city's Liftoff Houston competition. Photo courtesy of the City of Houston

Connecting medical professionals is about to get easier thanks to a new Houston company, Flourishing Nexus.

Next month, their digital platform, The Nexus, will debut to in a soft launch to a curated group of TMC employees.

“Think of it as a combination of existing platforms like LinkedIn, providing professional networking; Khan Academy, which provides excellent training and education; and a collaborative workspace like Google Workspace or Microsoft Teams, all enhanced by AI,” says Diane Nguyen.

Nguyen is a pharmacist by training, while her co-founder, Satid Thammasitboon, is an MD and master in health professions education.

The pair began working together in the health professions education space three years ago, but only established Flourishing Nexus in July of 2023. The company’s moniker refers to the concept of human flourishing.

“Our mission would be to promote human flourishing among health professionals,” says Thammasitboon.

The concept of human flourishing traces back at least to Aristotle, but The Nexus’ understanding of it is based on psychologist and educator Martin Seligman’s PERMA theory. The mnemonic stands for Positive Emotion, Engagement, Relationships, Meaning, and Accomplishment.

“We endeavor to bring these concepts of PERMA and human flourishing into the health professions space,” says Nguyen.

“Often our healthcare organizations or industries, when they hear health professionals are having issues with burnout, the response or reaction would be to increase incentive, financial support, or professional development to enhance resilience,” adds Thammasitboon. “We search for meaning we want to make a difference in the life of another rather than ‘everything is all about money.’”

Both professionals have globe-spanning careers. Thailand native Thammasitboon says that his endeavors have taken him across Europe, Southeast Asia, and East Asia, while Nguyen’s work has focused her attention on South America, sub-Saharan Africa, and Eastern Europe.

“I realized that the key to providing better outcomes and health care for the patients was really dependent on the continuing education and training of the staff,” Nguyen says.

Those experiences proved to be the roots from which The Nexus grew.

But the team’s colleagues abroad won’t be among the first The Nexus users. That distinction will belong to Houston’s rich community of medical pros. And when the platform soft launches in January, it will be with two awards already under its belt.

The Liftoff Houston Startup Business Plan competition took place last month. Nine finalists, mostly entrepreneurs from underrepresented backgrounds, were selected from among 100 applicants to compete in Liftoff’s Pitch Day. Not only was The Nexus among those competitors, it raked in a runner-up prize, as well as fan favorite in the innovation category.

Nguyen, who did the pitching, says that Liftoff helped Flourishing Nexus tremendously with both its preparation workshops and feedback from the judges.

“Sometimes you think you have a great idea but it’s not until you critically think about your own plan, analyze your plan, and prepare to pitch it that you really learn about it. This preparation helped us and strengthened our mission. Our business plan is much better,” says Thammasitboon.

Next up? Launching and growing The Nexus’ community. Nguyen also says they plan to participate in more competitions, including possibly Houston Community College’s Business Plan Competition. It’s one more way of bringing the abstract concept of human flourishing to a flesh and blood audience.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

NASA unveils Artemis III astronauts at Johnson Space Center in Houston

To the moon

NASA on Tuesday, June 9, revealed the crew for its Artemis III mission, the next step in the space agency's plan to eventually land astronauts on the moon.

The announcement came two months after Artemis II's record-breaking trip around the moon that surpassed the distance record of Apollo 13.

NASA's Randy Bresnik, Frank Rubio, Andre Douglas and the European Space Agency's Luca Parmitano won't fly to the moon or land on the surface. Instead, they’ll orbit Earth while practicing docking their Orion capsule with two lunar landers.

“To the Artemis III crew, we wish you Godspeed on the journey ahead,” said NASA administrator Jared Isaacman.

Elon Musk’s SpaceX and Jeff Bezos’ Blue Origin are racing to deliver the lunar landers. The two-week demo is targeted for 2027. Blue Origin suffered a recent setback when its massive rocket exploded during an engine-firing test on the launch pad in Florida, shaking nearby homes and illuminating the sky with an orange fireball.

NASA's Jeremy Parsons said the setback is a learning opportunity and that the space agency is confident Blue Origin's rocket will be ready in time.

NASA's Artemis program aims to return astronauts to the moon's surface for the first time since the 1970s. A recent revamp of the program announced by Isaacman aims to fast-track it similarly to the Apollo era, adding the upcoming spaceflight around Earth before eyeing a lunar landing in 2028.

“We are certainly humbled as a crew to be able to be your crew that executes this Artemis III mission in space,” said Bresnik, Artemis III commander.

Added Douglas, mission specialist: “My brain — it is going a mile a minute right now. But my heart, it is so warm. It is so full."

In May, NASA awarded hundreds of millions of dollars in contracts to four companies, including Blue Origin, to build landers, rovers and drones for a future moon base. Isaacman said the goal of the moon base is to lay the foundation for a Mars expedition.

Meta to bring $115 million AI data center training initiative to Houston

ai workforce

Meta and Associated Builders and Contractors have entered into a partnership to invest $115 million in training programs for the construction of AI data centers, with a portion of the project launching in Houston.

The companies announced June 8 that they would open America’s Workforce Academies at ABC chapter training centers in Houston; Indianapolis; Baton Rouge, Louisiana; and Columbus, Ohio.

The academies will offer career readiness and safety training, plus five weeks of hands-on education. Participants who complete the program will be granted a job offer from contractors working on Meta projects.

“The AI revolution is bringing change but also historic opportunities,” Dina Powell McCormick, Meta president and vice-chairman, said in a news release. “Skilled workers electrified rural America one pole at a time. They manned the factories that built the arsenal that won World War II. Now a new generation will pour the foundations and lay the fiber that secures American strength in this new age.”

Overall, the Meta and ABC aim for the academies to build a more sustainable pipeline of skilled construction workers and ensure safety and job readiness for the surging number of data center projects underway.

“This new program is an innovative talent solution that is a critical part of addressing the construction industry’s ongoing workforce shortage and creates an accelerated, new-entrant strategy for job seekers ... The sustained demand for data center construction technicians means the industry needs an all-of-the-above approach to address this shortage and grow the construction talent pool,” Michael Bellaman, ABC president and CEO, added in the release.

In Texas, Meta, the parent company of Facebook and Instagram, has launched or broken ground on data centers in El Paso, Fort Worth and Temple. The company announced in March that it planned to grow its El Paso Data center by 1 gigawatt, representing more than a $10 billion investment.

Apart from Meta, Texas has attracted data center development to power other giants like Google and Amazon in recent years. In turn, Texas has been predicted to become the biggest data center market. Commercial real estate services provider JLL reported this spring that the state could topple Northern Virginia as the world’s largest data-center market by 2030. Similarly, CBRE predicted that Houston's data center capacity could double by 2028. Read more here.

New Houston biotech co. lands $30M for pulmonary fibrosis drug

drug money

Most of us can claim a scar or two on our bodies. But when scarring develops inside the body, it’s known as a fibrotic disorder. A freshly launched Houston company, Oorja Bio Inc., is working on a treatment that can help to repair cells and reduce the damage wrought by the growth of fibrotic tissue in patients.

Late last month, Oorja Bio hit the scene with a pair of big announcements. Not only has the company raised a $30 million Series A thanks to founding investor California-based Westlake BioPartners, but it has also already paved the way for a Phase 2 study to take place this year.

Oorja Bio received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), allowing the company to test its treatment in patients with idiopathic pulmonary fibrosis (IPF), a scarring of the lung tissue. IPF affects more than 150,000 adults in the United States and can result in a range of symptoms from shortness of breath to organ failure and death as it progresses.

Oorja Bio’s lead drug candidate, ORJ-001, was shown in a Phase 1 in-human trial to demonstrate “therapeutically relevant exposure and favorable tolerability” in 64 healthy adult volunteers in whom it was administered daily or weekly, according to a news release. Pre-clinical studies of ORJ-001 showed durable target tissue engagement and biomarker activity in bleomycin-induced lung fibrosis.

Administered subcutaneously, ORJ-001 is intended to improve and even restore function in cells that can reduce the signaling that causes IPF. It stops advancement of IPF and also allows for tissue repair. Currently available treatments for the disease can slow the development of IPF down, but do not address the declining lung function that’s inherent in its progression.

“The clinical and preclinical results from our studies to date give us confidence that ORJ-001 represents a novel treatment approach with the potential to repair and reverse fibrosis and modify disease progression in IPF,” Dr. Janethe Pena, CMO of Oorja Bio, said in the release.

“Our team is energized to deliver on our goal of redefining the future of fibrotic diseases, beginning with ORJ-001,” CEO and founder Sujay Kango added. “As we advance ORJ-001 in the clinic, we are embracing the paradigm shift in our biological understanding of IPF pathology that aligns with the central role of the alveolar epithelium. ORJ-001 was designed with this biology in mind and may provide, for the first time, a therapeutic intervention that repairs and reverses fibrosis and promotes disease modification.”

Most patients live only three to five years following their IPF diagnosis. Soon, ORJ-001 and Oorja Bio could give them a fighting chance.